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Background
Herditary Angioedema (HAE) is a rare disorder
(1:10,000 – 1:50,000) characterized by episodic, localized
e d e m ao fs k i no rm u c o s ao fa i r w a y ,g e n i t o u r i n a r yt r a c t
or gastrointestinal tract. It is due to inherited deficiency
of the serpin known as C1 Inhibitor leading to unop-
posed kallikrein, producing excess bradykinin which
binds to G-protein coupled receptors known as B1 and
B2 receptors. Icatabant, a ten amino acid peptide analo-
gue of bradykinin is an effective blocker of the B2 recep-
tor and has been shown to provide rapid and complete
relief of symptoms compared to Tranexamic acid (Fast-
1) or placebo (Fast-2). Rapid relief of laryngeal edema
was confirmed in the open label arm. A new trial (Fast-
3) has begun. Primary Objective are to compare icati-
bant vs placebo on the time to symptom relief using a 3
symptom Visual Analog Scale (VAS) score during mod-
erate to very severe acute cutaneous and/or abdominal
attacks in patients with type I or type II hereditary
angioedema (HAE). Secondary Objectives are to com-
pare the global outcome following treatment with icati-
bant vs placebo using patient-reported (single symptom
and 8 symptom composite score) and physician-reported
outcome measures at 4 and 8 hours; to compare the
time to almost complete symptom relief following treat-
ment with icatibant vs placebo during moderate to very
severe acute cutaneous and/or abdominal attacks; to
assess safety and tolerability of icatibant vs placebo; and
to assess the efficacy and safety of open-label icatibant
treatment in patients experiencing laryngeal edema
attacks. 88 patients, aged 18 or older, with an attack of
at least moderate severity os skin, abdomen or larynx/
pharynx will be randomized to double-blind treatment
with either 30 mg of Icatabant SC or placebo.
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